Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Interest Expenses (2016 - 2024)

Historic Interest Expenses for Fortress Biotech (FBIO) over the last 9 years, with Q4 2024 value amounting to $2.7 million.

  • Fortress Biotech's Interest Expenses rose 260000.0% to $2.7 million in Q4 2024 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 80000.0%. This contributed to the annual value of $2.8 million for FY2024, which is 83333.33% up from last year.
  • As of Q4 2024, Fortress Biotech's Interest Expenses stood at $2.7 million, which was up 260000.0% from $100000.0 recorded in Q2 2024.
  • In the past 5 years, Fortress Biotech's Interest Expenses registered a high of $2.7 million during Q4 2024, and its lowest value of $100000.0 during Q2 2023.
  • In the last 3 years, Fortress Biotech's Interest Expenses had a median value of $100000.0 in 2023 and averaged $514285.7.
  • The largest annual percentage gain for Fortress Biotech's Interest Expenses in the last 5 years was 260000.0% (2024), contrasted with its biggest fall of 0.0% (2024).
  • Quarter analysis of 3 years shows Fortress Biotech's Interest Expenses stood at $400000.0 in 2021, then crashed by 75.0% to $100000.0 in 2023, then soared by 2600.0% to $2.7 million in 2024.
  • Its Interest Expenses was $2.7 million in Q4 2024, compared to $100000.0 in Q2 2024 and $100000.0 in Q1 2024.